Literature DB >> 8018542

Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo.

H J Hussey1, M J Tisdale.   

Abstract

The effect of the polyunsaturated fatty acids (PUFAs) linoleic acid (LA) and arachidonic acid (AA) on the growth of two murine colon adenocarcinoma cell lines (MAC26 and MAC13) has been determined both in vitro and in vivo. When the serum concentrations in the medium became growth limiting, low concentrations (18-33 microM) of both PUFAs were growth stimulatory to both cell lines, while higher concentrations were growth inhibitory. Growth stimulation by AA in both cell lines, and by LA in MAC13, was effectively inhibited by both the cyclo-oxygenase and lipoxygenase inhibitor indomethacin, and the lipoxygenase inhibitor BWA4C in a dose-dependent manner. The most effective inhibition was exerted by BWA4C, suggesting metabolism of both PUFAs through the lipoxygenase pathway for growth stimulation. In vivo studies using the MAC26 tumour showed a significant stimulation of tumour growth when LA was administered orally at concentrations higher than 0.4 g kg-1 day-1. Higher concentrations did not produce a further increase in tumour growth rate. This suggests that there is a threshold dose for growth stimulation by LA which, together with that in the diet, amounted to 3.8% of the total caloric intake. The increase in tumour volume induced by LA arose from a reduction in the potential doubling time from 41 to 28 h and was effectively reversed by indomethacin (5 mg kg-1). These results suggest that PUFAs may play an important role in tumour growth and may offer a potential target for the development of chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018542      PMCID: PMC2033311          DOI: 10.1038/bjc.1994.241

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Eicosanoids and linoleate-enhanced growth of mouse mammary tumor cells.

Authors:  D K Buckman; N E Hubbard; K L Erickson
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1991-11       Impact factor: 4.006

2.  Mammary carcinogenesis in rats fed different amounts and types of fat.

Authors:  A E Rogers; W C Wetsel
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

3.  Cell loss from several types of solid murine tumour: comparison of 125I-iododeoxyuridine and tritiated thymidine methods.

Authors:  A C Begg
Journal:  Cell Tissue Kinet       Date:  1977-09

4.  Tumor promotion by dietary fat in azoxymethane-induced colon carcinogenesis in female F344 rats: influence of amount and source of dietary fat.

Authors:  B S Reddy; Y Maeura
Journal:  J Natl Cancer Inst       Date:  1984-03       Impact factor: 13.506

5.  Effect of dietary fat on growth kinetics of transplantable mammary adenocarcinoma in BALB/c mice.

Authors:  H Gabor; L A Hillyard; S Abraham
Journal:  J Natl Cancer Inst       Date:  1985-06       Impact factor: 13.506

6.  Carcinogen-induced lesions in the rat pancreas: effects of varying levels of essential fatty acid.

Authors:  B D Roebuck; D S Longnecker; K J Baumgartner; C D Thron
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

7.  Requirement of essential fatty acid for mammary tumorigenesis in the rat.

Authors:  C Ip; C A Carter; M M Ip
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

8.  Arachidonic acid and docosahexaenoic acid are increased in human colorectal cancer.

Authors:  J P Neoptolemos; D Husband; C Imray; S Rowley; N Lawson
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

9.  Kinetics of the inhibition of tumour growth in mice by eicosapentaenoic acid-reversal by linoleic acid.

Authors:  E A Hudson; S A Beck; M J Tisdale
Journal:  Biochem Pharmacol       Date:  1993-06-09       Impact factor: 5.858

10.  Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease.

Authors:  A Chaudry; S McClinton; L E Moffat; K W Wahle
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

View more
  8 in total

1.  Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.

Authors:  Chinthalapally V Rao; Naveena B Janakiram; Altaf Mohammed
Journal:  Curr Colorectal Cancer Rep       Date:  2012-12

2.  In-silico and in-vitro studies on the efficacy of mangiferin against colorectal cancer.

Authors:  Rohini Samadarsi; Linus Augustin; Chandan Kumar; Debjani Dutta
Journal:  BMC Chem       Date:  2022-06-07

3.  Mechanism of the anti-tumour effect of 2,3,5-trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504).

Authors:  H J Hussey; M J Tisdale
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Differential effect of polyunsaturated fatty acids on cell proliferation during human epithelial in vitro carcinogenesis: involvement of epidermal growth factor receptor tyrosine kinase.

Authors:  S Mollerup; A Haugen
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  Inhibition of tumour growth by lipoxygenase inhibitors.

Authors:  H J Hussey; M J Tisdale
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

6.  Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).

Authors:  H J Hussey; M C Bibby; M J Tisdale
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

7.  Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid.

Authors:  W G Jiang; S Hiscox; M B Hallett; C Scott; D F Horrobin; M C Puntis
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

8.  Human liver cancer cells and endothelial cells incorporate iodised oil.

Authors:  S Bhattacharya; A P Dhillon; M C Winslet; B R Davidson; N Shukla; S D Gupta; R Al-Mufti; K E Hobbs
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.